Athersys Reports Interim Results From Phase 2 MultiStem Cell Therapy

(RTTNews) - Athersys Inc. (ATHX) announced interim results from its exploratory Phase 2 clinical study of the intravenous administration of MultiStem cell therapy to treat patients who have suffered an ischemic stroke. With respect to the primary and secondary endpoints, the cell therapy did not show a difference at 90 days compared to placebo. The company said the study results demonstrated favorable safety and tolerability for MultiStem, consistent with prior studies.

Gil Van Bokkelen, CEO at Athersys, said: "While the trial did not achieve the primary or component secondary endpoints, we believe the evidence indicating that patients who received MultiStem treatment early appeared to exhibit meaningfully better recovery is very important and promising. The results appear to confirm that our window of intervention with MultiStem therapy may extend well beyond the limits of current care."